Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiqing Luo has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Human Umbilical Cord Mesenchymal Stem Cells Alleviate Autoimmune POI Associated With Downregulated UBE2N ‐Mediated Ovarian Inflammation

    by Jinwei Li, Xianghui Wen, Jiaoshi Zhao, Min Gao, Xubin Hao, Shenghui Wen, Liuzhong Zhou, Xinyu Wu, Xiqing Luo, Shuangyan Cao, et al.

    Objective: To evaluate the therapeutic efficacy of human umbilical cord‐derived mesenchymal stem cells (hUC‐MSCs) in a murine model of autoimmune premature ovarian insufficiency (POI), and to investigate the association between ubiquitin‐conjugating enzyme E2N (UBE2N) expression and disease progression as well as treatment response. Methods: Autoimmune POI was induced in female BALB/c mice by zona pellucida glycoprotein 3 peptide (pZP3) immunization. Thirty mice were randomly assigned to Control, POI Model, and hUC‐MSC Treatment groups. Treated mice received weekly tail vein injections of hUC‐MSCs (1 × 10 6 cells/mouse) for 4 weeks. Estrous cyclicity, fertility, ovarian histopathology, peripheral Th17/Treg balance, and the expression of IL‐17, IFN‐γ, and UBE2N were evaluated by immunohistochemistry. Results: Compared with the POI Model group, hUC‐MSC treatment restored regular estrous cyclicity, improved ovarian morphology, and increased litter size. Flow cytometry showed correction of the abnormal Th17/Treg imbalance in treated mice. Immunohistochemistry revealed marked upregulation of UBE2N, IL‐17, and IFN‐γ in ovarian tissue from POI mice, whereas hUC‐MSC administration significantly reduced their expression. No treatment‐related adverse effects were observed. Conclusion: hUC‐MSCs effectively alleviated ovarian dysfunction in autoimmune POI mice. The therapeutic improvement was accompanied by systemic immune rebalancing and decreased aberrant ovarian UBE2N expression, indicating UBE2N as a candidate inflammatory biomarker associated with autoimmune ovarian injury and immune dysregulation.

  • Open Access

    A Database-Derived Phthalate Ester–Ankylosing Spondylitis Signature Identifies an AP-1/CXCL8 Inflammatory Classical-Monocyte Program

    by Xiqing Luo, Xuqi Zheng, Wenyu Xu, Dan Guo, Xinlei Jia, Jieruo Gu, Xiaoyi Zhao, Yutong Jiang

    Objectives: We tested whether a database-derived phthalate ester (PAE)–ankylosing spondylitis (AS) candidate panel identifies an inflammatory transcriptional program and characterized its transcription-factor (TF) architecture. Methods: Machine learning prioritization and repeated nested cross-validation were followed by locked-model transfer from GSE73754 to GSE25101. Donor-level single-cell analyses included 96,746 peripheral blood mononuclear cells from 10 AS and 29 healthy-control donors (GSE194315), with corroboration assessed in 25 additional baseline AS patients (GSE277117). Results: Within classical monocytes, the continuous signature covaried with panel-excluded TNF-α/NF-κB signaling (ρ = 0.571; q = 0.000729), inflammatory response (ρ = 0.447; q = 0.0108), and eight of 10 AP-1-related TF activities. Target-excluded TF activities covaried with CXCL8 (8/10) and IL1B (10/10). AP-1-gene/CXCL8 co-expression received partial corroboration in the additional AS cohort (JUN–CXCL8: ρ = 0.92). Among 16 genes prioritized from 473 shared candidates, CXCL8, IL2RB, STAT5B and TNF were stable. The locked 14-gene model achieved an area under the receiver-operating-characteristic curve of 0.770 (DeLong 95% confidence interval, 0.596–0.943), supporting partial rank transportability. Secondary analyses showed a lower CD56bright fraction among natural killer (NK) cells in AS (−2.699 percentage points; 95% confidence interval, −4.575 to −0.611; q = 0.0498) and reduced NK-cell JUN expression (log2 fold change = −0.995; adjusted p = 0.0497). Conclusions: The PAE–AS signature identifies an AP-1/CXCL8-associated classical-monocyte inflammatory program, with partial cross-cohort corroboration and secondary NK alterations, providing candidates for exposure-informed mechanistic studies.

  • Noncanonical Differentiation of Memory B Cells Drives Latent Tuberculosis Infection Reactivation Upon Tumor Necrosis Factor‐Alpha Inhibitor Therapy: An Integrative Transcriptomic Study

    by Xinyu Yu, Dong Liu, Xiqing Luo, Xianghui Wen, Zena Chen, Shude Chen, Budian Liu, Jinwei Li, Yuxuan Zhang, Jieruo Gu

    Aim: Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of autoimmune diseases, with latent tuberculosis infection (LTBI) reactivation being a significant unresolved issue. The pathogenic mechanisms are not fully understood. Integrated transcriptomic analysis could provide insights into monitoring tuberculosis progression after TNFi therapy and help reduce LTBI reactivation. Methods: We selected six transcriptomic datasets from studies related to TNFi treatment and tuberculosis. Pathway enrichment, pseudotime, and transcription factor analyses were performed to explore the underlying mechanisms. Results: Our analysis revealed distinct transcriptional changes in memory B cells during tuberculosis progression and TNFi therapy. In active tuberculosis (ATB), ROR1 + memory B cells were identified in a noncanonical differentiation trajectory, characterized by downregulation of B cell‐related genes (e.g., CD22, EBF1, MS4A1), reduced translational capacity, and suppression of immune response pathways, accompanied by upregulation of oxidative phosphorylation, which highlighted metabolic alterations during tuberculosis progression. A similar subtype also emerged in TNFi‐treated patients, suggesting that metabolic reprogramming of memory B cells may disrupt immune balance, thereby contributing to LTBI reactivation and ATB development following TNFi therapy. Conclusions: The study integrates bioinformatics and single‐cell RNA sequencing to reveal the role of memory B cells in ATB progression and TNFi treatment, offering insights into TNFi‐associated TB susceptibility and potential therapeutic targets.